# ICICI LOMBARD GEN INSURANCE CO (ICILOM)



CMP: ₹ 1890

Target: ₹ 2050 (8%)

Target Period: 12 months

July 22, 2024

## Market share gain amid healthy renewals aid overall growth

About the stock: ICICI Lombard is among the leading multi-line players in the general insurance space with  $\sim 10.6\%$  market share on an overall basis.

- Motor segment contributes over ~31% of total premium, health insurance contributes 34%
- The general insurer is among the most profitable and consistent in terms of return ratios with RoE of ~14% for a sustainable period

Q1FY25 performance: ICICI Lombard reported 20.4% YoY growth in gross direct premium to ₹7688 crore, higher than the industry, driven by motor segment amid healthy renewals in auto segment. Motor segment witnessed growth at 26.3% YoY with private car segment gaining traction. Health segment witnessed growth at 24.7% in Q1FY25 with strong business in employer-employee segment. Combined ratio reported at 102.3% vs 103.8% in Q1FY24. Guidance on combined ratio maintained at 101.5% at exit of Q4FY25.

#### **Investment Rationale**

- Market share gain aids premium accretion: Heightened competition in motor segment impacted business growth and thus market share in the past, however, with signs of easing competitive intensity and strong distribution moat especially in car segment, ICICI Lombard is well placed to sustain premium growth thereby witnessing gradual uptick in market share (higher than industry growth at 26.3% seen in Q1FY25). Retail health business gained momentum with traction in group business amid easing of aggressive pricing in the industry. Launch of new product in retail segment is expected to aid traction in premium growth in individual segment. Expect 15-17% CAGR in premium accretion in FY25-26E.
- Guidance on combined ratio maintained: Balancing business growth along with profitability has led to improvement in loss ratio in motor segment at 66.8% in Q1FY25 vs 69.8% in Q1FY24. With improvement in competitive environment in motor segment easing, management continues to remain comfortable with loss ratio at 65-70% for motor TP and 60-65% for motor OD. In health segment, group health has witnessed marginal improvement in loss ratio. Thus, combined ratio improvement is on track and management maintains its target to achieve combined ratio of 101.5% on the exit of FY25E.

#### Rating and Target Price

• Historically, combined ratio has remained an important contributor to valuation. Sustained recovery in market share and reduction in combined ratio to drive valuation. Declining competitive intensity in motor segment aiding business growth and pick-up in individual health business amid product launch remains growth levers. Overall, the insurer remains a good bet to play Indian general insurance industry with consistent profitability. We assign a multiple of ~1.7x FY26E float to arrive at a target of ₹ 2050 with a Hold rating.





| ₹ 93,826 crore |
|----------------|
| ₹ 11,960 crore |
| 1916 / 1266    |
| 10.0           |
|                |

#### Shareholding pattern Jun-23 Sep-23 Dec-23 Mar-24 Jun-24 Promoter 48.0 48 N 479 51.3 FII 22.0 22 4 23.0 23 1 239 DII 18.1 18.4 17.9 16.0 17.2 Others 11.9 9.7 7.1

|      | ~      |        | •           |           |        |        |          |          |       |   |
|------|--------|--------|-------------|-----------|--------|--------|----------|----------|-------|---|
| 2400 |        |        |             |           |        |        |          |          |       |   |
|      | 1      |        |             |           |        |        |          | w/ I     |       |   |
| 2000 | 1      |        |             |           |        | ,~~    |          | +        | 20000 | ) |
| 1600 | þ      | 1      | $^{\wedge}$ | MV '      |        | دراد   | may m    | 4        | 15000 | ) |
| 1200 | 1      |        | J. J.       | <b>^~</b> | اسا    |        |          |          | 10000 | , |
| 800  | 4      |        |             |           |        |        |          | Ť        | 10000 | ) |
| 400  | ł      |        |             |           |        |        |          | +        | 5000  |   |
| 0    | +      |        | _           | _         | _      | _      | _        | 4        | 0     |   |
|      | Jul-21 | Dec-21 | May-22      | Oct-22    | Mar-23 | Aug-23 | Jan-24   | Jun-24   |       |   |
|      | 늨      | င္ပ်   | ş           | ੪         | 늡      | ₽      | Ė        | ≟        |       |   |
|      |        | ŏ      | ž           | 0         | Σ      | Ā      | <u>~</u> | <u> </u> |       |   |
|      |        | ICIC   | 116         | mh        | ard    |        | N        | lift.    | Index |   |
|      |        | いしし    | I LU        | מווי      | uru    |        | ۱۰       | NII LV   | index |   |

#### Key risks

Price Chart

- (i) Slower than expected improvement in combined ratio
- (ii) Increase in competitive intensity to impact business momentum

#### Research Analyst

Vishal Narnolia vishal.narnolia@icicisecurities.com

Gaurav Singh gaurav.si@icicisecurities.com

Krishna Vyas krishna.vyas@icicisecurities.com

| Key Financial Summary      |         |         |         |         |                                 |         |         |                                  |  |
|----------------------------|---------|---------|---------|---------|---------------------------------|---------|---------|----------------------------------|--|
| ₹ crore                    | FY21    | FY22    | FY23    | FY24    | 3 Year<br>CAGR (FY21<br>- FY24) | FY25E   | FY26E   | 2 year CAGR<br>(FY24 -<br>FY26E) |  |
| Gross direct premium incom | 14003.1 | 17976.9 | 21025.1 | 24776.1 | 20.9                            | 28513.9 | 32926.4 | 15.3                             |  |
| Adjusted net profit        | 1473.1  | 1271.0  | 1756.9  | 1918.6  | 9.2                             | 2256.1  | 2530.0  | 14.8                             |  |
| Networth                   | 7435.5  | 9109.7  | 10392.2 | 11959.8 | 17.2                            | 13854.9 | 15980.1 | 15.6                             |  |
| EPS (Rs)                   | 32.4    | 25.9    | 35.2    | 38.9    |                                 | 45.8    | 51.4    |                                  |  |
| P/E (x)                    | 58.6    | 73.4    | 54.0    | 48.8    |                                 | 41.5    | 37.0    |                                  |  |
| RoE (%)                    | 21.3    | 14.5    | 17.5    | 16.3    |                                 | 16.1    | 15.6    |                                  |  |
| P/Float                    | 2.8     | 2.4     | 2.2     | 1.9     |                                 | 1.7     | 1.6     |                                  |  |
| P/GWP                      | 6.0     | 5.0     | 4.3     | 3.7     |                                 | 3.2     | 2.8     |                                  |  |

## j

#### Concall highlights and outlook

#### Motor segment

- Overall growth in the Motor segment was aided by strong growth in the old business. New book grew at ~16%-17%, whereas the old book grew at 33%.
- Motor segment witnessed higher than industry, thereby gaining market share. Industry is witnessing easing in pricing competitiveness
- Introduced long-term product offerings for private cars and two-wheelers.
  Advanced premium stands at ₹3456 crore
- Management remains comfortable with loss ratio in motor OD segment at 60-65% and for motor TP segment at 65-70%.

#### Health segment

- Leveraging favourable industry pricing and superior customer service, the company grew its Group Health - Employer, Employee segment by 31.1% in Q1FY25. The corporate group segment is showing positive underwriting outcomes.
- Aims to moderate loss ratio in the health segment through the launch of new health insurance solution "Elevate" powered by AI.
- Changes in regulations for non-banking channels have impacted disbursements and reduced sourcing particularly through the NBFC partners and unsecured segment.
- The company is diversifying its customer base in the health insurance segment as a higher concentration of younger base could hamper persistency. Thus, the focus would be to source healthy lives.
- The company has launched a new health insurance solution Elevate, a new Al-powered solution. Elevate boasts industry-leading features like unlimited coverage (infinite sum insured) and treatment options (infinite care), along with a jumpstart benefit (power booster jumpstart). The Al engine tailors coverage to individual customer profiles for optimal protection. To ensure widespread availability, the company launched Elevate through more than 200 events across the country leveraging their agency distribution network.
- In health segment, loss ratio is targeted to remain at ~70%, while loss ratio ranging from 94%-95% on a full year basis targeted for corporate health group book.

#### **Financials**

- Company's GDPI grew at 20.4% vs industry's growth of 13.3% in Q1FY25, Motor segment grew 26.3% vs industry growth of 12%, New private car and CV business grew at 13.4%/20.3% vs 3%/7.8% of industry growth respectively.
- Combined ratio trajectory seems to be improving as it stood at 102.3% for Q1FY25 compared to 103.8% for Q1FY24. The co expects it to be around 101.5 by end of FY25
- Company continues to maintain leadership position in segments of Engineering, Liability and Marine Cargo.
- Focus continued to grow with commercial viability in conjunction. Faster growth in old motor business (renewals) has led to better opex ratio
- The company's investment income jumped to INR 11.28 billion in Q1 FY25, up from a revised INR 8.44 billion in Q1 FY24. This increase reflects an update to insurance regulations in May 2024. Duration of investment book is at 5.48 years
- Reported lower opex which was driven by cost efficiency and product mix.
  It has improved by 7%-8% due lower cost of acquisition aided by growth of old motor book and portfolio configuration. The sustainability of such opex reduction is being monitored closely by the management
- The company's digital business grew 20.7% in Q1 and accounted for 4.9% of total revenue. The IL TakeCare app, a one-stop shop for insurance and wellness needs, has further fuelled this growth by reaching a significant milestone of 10 million downloads.



| Exhibit 1: Variance Analysis        |        |        |          |        |          |   |
|-------------------------------------|--------|--------|----------|--------|----------|---|
| Results Summary (₹ cr)              | Q1FY25 | Q1FY24 | YoY %    | Q4FY24 | QoQ %    | Comments  |
| Policyholders' Account              |        |        |          |        |          |   |
| Gross premium written               | 7931.1 | 6622.1 | 19.8     | 6263.1 | 26.6     | Healthy traction in motor segment aid premium                       |
| Net premium written                 | 5360.5 | 4467.6 | 20.0     | 4767.2 | 12.4     |   |
| Premium Earned (Net)                | 4503.9 | 3887.3 | 15.9     | 4368.3 | 3.1      |   |
| Income from investments (net)       | 844.6  | 621.6  | 35.9     | 789.7  | 7.0      | Healthy gains from equity as well as debt portfolio. Yield at 8.8%  |
| Other income                        | 3.5    | 29.2   | -88.0    | 7.5    | -53.0    |   |
| Total income                        | 5352.0 | 4538.0 | 17.9     | 5165.4 | 3.6      |   |
| Commission                          | 804.5  | 556.4  | 44.6     | 949.9  | -15.3    | Commission ratio high at 15%  |
| Opex relating to insurance business | 711.6  | 768.9  | -7.5     | 655.2  | 8.6      | Opex lower due to traction in old business                          |
| Incurred claims                     | 3334.4 | 2881.5 | 15.7     | 2998.7 | 11.2     | Loss ratio at 74% vs 74.1%  |
| Total expenses                      | 4850.5 | 4206.8 | 15.3     | 4603.8 | 5.4      |   |
| Underwriting profit/ (loss)         | -346.6 | -319.5 | 8.5      | -235.6 | 47.1     | Combined ratio at 102.3%  |
| Operating profit/ (loss)            | 501.5  | 331.2  | 51.4     | 561.5  | -10.7    |   |
| Shareholders' Account               | Q1FY25 | Q1FY24 | YoY %    | Q4FY24 | QoQ %    |   |
| Income in shareholder's account     | 754.4  | 516.8  | 46.0     | 795.3  | -5.1     |   |
| Total Expenses                      | -19.6  | -3.2   | 510.0    | 97.5   | -120.1   |   |
| Profit before taxes                 | 774.0  | 520.0  | 48.8     | 697.8  | 10.9     |   |
| Provision for taxes                 | 193.6  | 129.7  | 49.3     | 178.3  | 8.6      |   |
| Profit after tax                    | 580.4  | 390.4  | 48.7     | 519.5  | 11.7     | Healthy traction in premium and investment income aid profitability |
| Analytical ratios (reported)        | Q1FY25 | Q1FY24 | YoY %    | Q4FY24 | QoQ %    |   |
| Solvency ratio                      | 2.56   | 2.53   | 3 bps    | 2.62   | -6 bps   |   |
| Claim ratio                         | 74.03  | 74.13  | -9 bps   | 68.65  | 539 bps  |   |
| Expense ratio                       | 26.80  | 26.60  | 20 bps   | 32.80  | -600 bps |   |
| Net retention ratio                 | 67.60  | 67.50  | 10 bps   | 76.10  | -850 bps |   |
| Combined ratio                      | 102.30 | 103.80 | -150 bps | 102.20 | 10 bps   |   |



# **Financial Summary**

| Exhibit 2: Policyholder's Account |         |         |         |         |         |  |  |  |  |  |
|-----------------------------------|---------|---------|---------|---------|---------|--|--|--|--|--|
| (Year-end March)                  | FY22    | FY23    | FY24    | FY25E   | FY26E   |  |  |  |  |  |
| Gross direct premium income       | 17976.9 | 21025.1 | 24776.1 | 28513.9 | 32926.4 |  |  |  |  |  |
| Net Earned Premium                | 13032.1 | 14822.8 | 16866.5 | 19552.8 | 22823.9 |  |  |  |  |  |
| Investment income                 | 3097.8  | 3272.1  | 2885.6  | 3174.2  | 3491.6  |  |  |  |  |  |
| Total income                      | 16129.8 | 18094.9 | 19752.1 | 22727.0 | 26315.5 |  |  |  |  |  |
| Claims                            | 9781.9  | 10725.7 | 11939.5 | 13755.8 | 16010.2 |  |  |  |  |  |
| Commission                        | 633.9   | 472.2   | 3089.0  | 3359.1  | 3893.7  |  |  |  |  |  |
| Operating expense                 | 3920.1  | 4486.9  | 2817.7  | 3346.0  | 3900.9  |  |  |  |  |  |
| Total expense                     | 14335.9 | 15712.6 | 17846.2 | 20461.0 | 23804.8 |  |  |  |  |  |

Source: Company, ICICI Direct Research

| Exhibit 3: Shareholder's Account |        |        |        |        |        |  |  |  |  |
|----------------------------------|--------|--------|--------|--------|--------|--|--|--|--|
| (Year-end March)                 | FY22   | FY23   | FY24   | FY25E  | FY26E  |  |  |  |  |
| Operating profit/(Loss)          | 1793.9 | 2410.2 | 1905.9 | 2266.1 | 2510.7 |  |  |  |  |
| Income from Investments          | 703.2  | 731.7  | 844.8  | 1016.6 | 1177.7 |  |  |  |  |
| Other income - misc income       | 3.0    | 43.9   | 5.2    | 5.2    | 5.2    |  |  |  |  |
| Total Income                     | 2500.1 | 3185.8 | 2755.9 | 3287.9 | 3693.6 |  |  |  |  |
| Total Expenses                   | 816.6  | 1045.4 | 200.7  | 230.9  | 265.5  |  |  |  |  |
| Profit Before Tax                | 1683.5 | 2140.4 | 2555.2 | 3057.0 | 3428.1 |  |  |  |  |
| Tax                              | 412.5  | 383.5  | 636.6  | 800.9  | 898.2  |  |  |  |  |
| Profit After Tax                 | 1271.0 | 1756.9 | 1918.6 | 2256.1 | 2530.0 |  |  |  |  |

Source: Company, ICICI Direct Research

| Exhibit 4: Balance s | heet    |         |         |         | ₹ crore |  |  |
|----------------------|---------|---------|---------|---------|---------|--|--|
| (Year-end March)     | FY22    | FY23    | FY24    | FY25E   | FY26E   |  |  |
| Shareholders' Funds  |         |         |         |         |         |  |  |
| Share capital        | 490.9   | 491.1   | 492.7   | 492.7   | 492.7   |  |  |
| Reserve and surplus  | 8618.8  | 9901.1  | 11467.1 | 13362.2 | 15487.4 |  |  |
| Fair Value change    | 359.3   | 213.3   | 989.6   | 1188.7  | 1313.2  |  |  |
| Borrowings           | 255.0   | 35.6    | 35.0    | 35.0    | 35.0    |  |  |
| Total                | 9724.0  | 10641.1 | 12985.0 | 15079.3 | 17329.0 |  |  |
| Application of funds |         |         |         |         |         |  |  |
| Investments          |         |         |         |         |         |  |  |
| Shareholders         | 8917.9  | 9858.3  | 11586.9 | 12977.3 | 14534.6 |  |  |
| Policyholders        | 29868.4 | 33322.1 | 37320.4 | 41052.4 | 45157.7 |  |  |
| Fixed assets         | 577.5   | 564.0   | 700.9   | 770.9   | 848.0   |  |  |
| Deferred tax asset   | 345.6   | 265.3   | 292.6   | 292.6   | 292.6   |  |  |
| Current assets       | 11139.0 | 11076.5 | 13407.6 | 22588.6 | 29007.0 |  |  |
| Current liabilities  | 33066.8 | 35658.7 | 40235.2 | 50754.8 | 58608.9 |  |  |
| Provisions           | 8057.5  | 8786.5  | 10088.1 | 11847.8 | 13902.0 |  |  |
| Total                | 9724.0  | 10641.1 | 12985.0 | 15079.3 | 17329.0 |  |  |

Source: Company, ICICI Direct Research

| Exhibit 5: Key ratios       |       |       |       |       |       |
|-----------------------------|-------|-------|-------|-------|-------|
| (Year-end March)            | FY22  | FY23  | FY24  | FY25E | FY26E |
| Growth Ratios (%)           |       |       |       |       |       |
| Gross Direct Premium Income | 28.4  | 17.0  | 17.8  | 15.1  | 15.5  |
| Net Premium Income          | 30.1  | 13.7  | 13.8  | 15.9  | 16.7  |
| Operating Expenses          | 40.5  | 14.5  | -37.2 | 18.7  | 16.6  |
| PAT                         | -13.7 | 38.2  | 9.2   | 17.6  | 12.1  |
| BVPS                        | 13.5  | 14.0  | 14.7  | 15.8  | 15.3  |
| EPS                         | 25.9  | 35.2  | 38.9  | 45.8  | 51.4  |
| Profitability Ratios (%)    |       |       |       |       |       |
| Yield on Investment         | 10.9  | 9.8   | 8.1   | 8.1   | 8.2   |
| Claims ratio                | 58.5  | 58.1  | 59.4  | 70.3  | 70.3  |
| Commission To NEP           | 4.9   | 3.2   | 18.3  | 17.2  | 17.1  |
| Opex to NEP                 | 30.1  | 30.3  | 16.7  | 17.1  | 17.1  |
| Combined Ratio              | 108.8 | 104.3 | 103.3 | 102.2 | 101.9 |
| Balance Sheet Ratios (%)    |       |       |       |       |       |
| RoE                         | 14.5  | 17.5  | 16.3  | 16.1  | 15.6  |
| Investment Leverage         | 4.2   | 4.2   | 4.1   | 3.9   | 3.7   |
| Solvency Ratio (x)          | 2.5   | 2.5   | 2.6   | 2.9   | 2.9   |
| Valuation Ratio             |       |       |       |       |       |
| P/B                         | 10.2  | 9.0   | 7.8   | 6.8   | 5.9   |
| P/E                         | 73.4  | 54.0  | 48.8  | 41.5  | 37.0  |
| P/float                     | 2.4   | 2.2   | 1.9   | 1.7   | 1.6   |
| P/GWP                       | 5.0   | 4.3   | 3.7   | 3.2   | 2.8   |

Source: Company, ICICI Direct Research



#### **RATING RATIONALE**

ICICI Direct endeavors to provide objective opinions and recommendations. ICICI Direct assigns ratings to its stocks according -to their notional target price vs. current market price and then categorizes them as Buy, Hold, Reduce and Sell. The performance horizon is two years unless specified and the notional target price is defined as the analysts' valuation for a stock

Buy: >15%

Hold: -5% to 15%;

Reduce: -15% to -5%;

Sell: <-15%



Pankaj Pandey

Head – Research

pankaj.pandey@icicisecurities.com

ICICI Direct Research Desk, ICICI Securities Limited, Third Floor, Brillanto House, Road No 13, MIDC, Andheri (East) Mumbai – 400 093 research@icicidirect.com



#### ANALYST CERTIFICATION

I/We, Vishal Narnolia, MBA, Gaurav Singh, PGDM, Krishna Vyas, MMS, Research Analysts Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products.

ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager and Research Analyst. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH00000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidiaries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on www.icicibank.com.

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by Sebi and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk-free return to the investors.

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal

Contact number: 022-40701000 E-mail Address: complianceofficer@icicisecurities.com

For any queries or grievances: Mr. Bhavesh Soni Email address: headservicequality@icicidirect.com Contact Number: 18601231122

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Retail Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Institutional Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its associates or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report.